



#1602, 49, Achasan-ro, Seongdong-gu, Seoul, Republic of Korea (04790)  
Tel: +82-2-573-8986  
Email: [daniel.choi@wellehaus.com](mailto:daniel.choi@wellehaus.com)

March 21, 2022

Federal Communications Commission  
445 12<sup>th</sup> Street SW  
Washington, DC 20554

Subject: Limited Agency Agreement  
**WELLE Co., Ltd**  
FCC ID: **2A5SOW201T**

To Whom It May Concern:

We, **WELLE Co., Ltd**, hereby authorized Intertek Testing Services to act as our Agent for the purpose of preparing application for FCC ID number **2A5SOW201T** under all applicable parts of the FCC rules and regulations.

The effective date of this limited agency agreement is **March 21, 2022**. The Limited Agency Agreement expires on **June 20, 2022**, unless sooner terminated or extended by written notice to Intertek Testing Services and the Federal Communications Commission.

This is to advise that we are in full compliance with the Anti-Drug Abuse Act. The applicant is not subject to a denial of federal benefits pursuant to Section 5301 of the Anti-Drug Act of 1988, 21 U.S.C. 862, and no party to the application is subject to a denial of federal benefits pursuant to that section.

If you have any questions or comments, please do not hesitate to contact me.

Sincerely,

A handwritten signature in black ink, appearing to read "Daniel Choi".

*DANIEL CHOI  
Director of Research Institute*